|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent ICAD insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why ICAD insider buys are important for investors to follow.
Date | Insider | Price | Amount |
3-3-2022 Insider Buy |
Timothy Norris Irish Director |
$4.63
CAGR »
|
$25,465.00 5,500 shares |
12-9-2021 Insider Buy |
Nathaniel Dalton Director |
$7.24
CAGR »
|
$49,956.00 6,900 shares |
12-8-2021 Insider Buy |
Michael S. Klein CHIEF EXECUTIVE OFFICER |
$7.38
CAGR »
|
$99,445.50 13,475 shares |
12-8-2021 Insider Buy |
Susan Alyson Wood Director |
$7.31
CAGR »
|
$10,965.00 1,500 shares |
8-23-2017 Insider Buy |
DR Lawrence Howard Director |
$3.33
CAGR »
|
$33,300.00 10,000 shares |
11-14-2016 Insider Buy |
Kenneth M. Ferry CEO |
$3.50
CAGR »
|
$35,000.00 10,000 shares |
3-4-2016 Insider Buy |
Kevin C. Burns President/ CFO/ COO |
$4.44
CAGR »
|
$44,400.00 10,000 shares |
3-4-2016 Insider Buy |
Kenneth M. Ferry CEO |
$4.45
CAGR »
|
$111,250.00 25,000 shares |
8-26-2013 Insider Buy |
Kenneth M. Ferry President, CEO |
$5.55
CAGR »
|
$27,746.50 5,000 shares |
5-3-2013 Insider Buy |
Kevin C. Burns Executive VP of Finance, CFO |
$5.19
CAGR »
|
$15,046.50 2,900 shares |
8-24-2012 Insider Buy |
Kevin C. Burns Exeuctive VP of Finance, CFO |
$2.08
CAGR »
|
$31,125.00 15,000 shares |
8-17-2012 Insider Buy |
Kevin C. Burns Executive VP of Finance, CFO |
$2.90
CAGR »
|
$83,883.71 28,939 shares |
6-1-2012 Insider Buy |
Elliot J. Mba Sussman, M.D. Director |
$0.51
CAGR »
|
$11,138.73 21,801 shares |
5-29-2012 Insider Buy |
Elliot J. Mba Sussman, M.D. Director |
$0.49
CAGR »
|
$6,666.45 13,500 shares |
5-24-2012 Insider Buy |
Elliot J. Mba Sussman, M.D. Director |
$0.50
CAGR »
|
$7,500.00 15,000 shares |
5-22-2012 Insider Buy |
Elliot J. Mba Sussman, M.D. Director |
$0.51
CAGR »
|
$2,531.64 5,000 shares |
5-18-2012 Insider Buy |
Elliot J. Mba Sussman, M.D. Director |
$0.50
CAGR »
|
$7,460.25 15,000 shares |
5-16-2012 Insider Buy |
Elliot J. Mba Sussman, M.D. Director |
$0.50
CAGR »
|
$7,402.34 14,900 shares |
5-14-2012 Insider Buy |
Elliot J. Mba Sussman, M.D. Director |
$0.47
CAGR »
|
$7,358.26 15,575 shares |
Also See: Institutional Holders of ICAD
Also See: SEC filings
Below we present the annualized performance delivered by ICAD stock since 3-3-2022 (the date of the most recent
insider purchase). The performance of the investment from the time ICAD insider buying occurred is the ultimate
test of whether insiders were right about ICAD being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/04/2022 |
|
End date: |
04/24/2024 |
|
Start price/share: |
$4.20 |
|
End price/share: |
$1.56 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-62.86% |
|
Average Annual Total Return: |
-37.05% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$3,714.55 |
|
Years: |
2.14 |
|
ICAD Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent ICAD insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding ICAD
|
|